Structure–Activity Studies of a Novel Opioid Cyclic Hexapeptide Modified at Gly 3 : Identification of Highly Potent Agonists or Antagonists of Opioid Receptors
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c02401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Qinqin Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Con…. Hauptthemen laut MEDLINE: Peptides, Cyclic, Receptors, Opioid, Analgesics, Opioid, Narcotic Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Science and Technology Program of Gansu Province, National Natural Science Foundation of China, Key Talent Project of Gansu Province.
Abstract (Originalsprache)
Subtle structural modifications at the 3-position of opioid peptides have been reported to modulate their receptor binding affinity and functional activity. Our previous work identified a novel cyclic hexapeptide, Tyr-c[D-Lys-Gly-Phe-Asp]-D-Pro-NH2, as a multitarget full agonist at μ-, κ-, and δ-opioid receptors (MOR, KOR, and DOR). In the present study, 16 novel analogs of this hexapeptide were synthesized by replacing the Gly3 residue with phenylalanine and its derivatives to investigate their structure-activity relationships. Functional characterization demonstrated that these modifications generated analogs exhibiting varying selectivity and efficacy profiles at opioid receptors. Notably, analog 9 containing p-F-Phe3 exhibited MOR and KOR agonism/DOR antagonism and produced potent antinociception following peripheral administration, with reduced antinociceptive tolerance, physical dependence, and respiratory depression. Surprisingly, analog 11 containing p-Br-Phe3 acted as a potent and selective MOR antagonist. Pharmacological blockade of the peripheral MOR by analog 11 significantly attenuated fentanyl-induced antinociceptive tolerance, highlighting its therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, and State Key Laboratory of Animal Disease Control and Prevention College of Veterinary Medicine, Lanzhou University…
- Key Laboratory of Translational Research in Cell and Gene Therapy of Shaanxi Higher Education Institutions, Department of Cell Biology and Genetics School of Basic Medical Science, Xi'an Medical University, No.1 Xinwang…
ORCID-Profile: Quan Fang
Förderung
- Science and Technology Program of Gansu Province
- National Natural Science Foundation of China
- Key Talent Project of Gansu Province
Zitieren
APA
Zhang, Q., Zhang, M., Hu, S., Wang, Z., Wang, X., Wu, S., Ding, W., Li, N., Zhang, N., Xu, B., & Fang, Q. (2026). Structure–Activity Studies of a Novel Opioid Cyclic Hexapeptide Modified at Gly 3 : Identification of Highly Potent Agonists or Antagonists of Opioid Receptors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02401
Vancouver
Zhang Q, Zhang M, Hu S, Wang Z, Wang X, Wu S, et al. Structure–Activity Studies of a Novel Opioid Cyclic Hexapeptide Modified at Gly 3 : Identification of Highly Potent Agonists or Antagonists of Opioid Receptors. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02401
BibTeX
@article{Zhang2026,
author = {Zhang, Qinqin and Zhang, Mengna and Hu, Sha and Wang, Zefei and Wang, Xia and Wu, Shuyuan and Ding, Weifan and Li, Ning and Zhang, Nan and Xu, Biao and Fang, Quan},
title = {Structure–Activity Studies of a Novel Opioid Cyclic Hexapeptide Modified at Gly 3 : Identification of Highly Potent Agonists or Antagonists of Opioid Receptors},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c02401}
}
EUVIMED